Bavarian Nordic A/S
207 articles about Bavarian Nordic A/S
The vaccine was effective against previous COVID-19 variants but lacked efficacy against new ones, the company announced Thursday, leaving the booster no commercially viable options.
The Danish company’s vaccine candidate met all co-primary endpoints in a late-stage study in adults and adolescents just months after publishing trial data for elderly patients, as it seeks to challenge Valneva.
Bavarian Nordic Reports Positive Phase 3 Topline Results for Chikungunya Virus Vaccine in Adults and Adolescents
Bavarian Nordic A/S announced positive topline results from a randomized, double-blind, placebo-controlled Phase 3 clinical trial of its virus-like particle -based chikungunya virus vaccine candidate, CHIKV VLP in adults and adolescents aged 12 to 64 years of age.
Bavarian Nordic Receives USD 120 Million Contract for the Manufacturing of Smallpox and Mpox Vaccine from the U.S. Government
Bavarian Nordic A/S announced that the U.S. Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services, has placed a new order valued at USD 120 million, primarily covering the manufacturing of new bulk product for the Company’s smallpox/mpox vaccine.
The Danish vaccine maker’s respiratory syncytial virus candidate did not meet all primary endpoints in a late-stage study in older adults and the company is discontinuing the program.
Bavarian Nordic A/S (OMX: BAVA) today reported topline results from a Phase 3 non-inferiority clinical trial of ABNCoV2, a VLP-based, non-adjuvanted COVID-19 booster vaccine candidate.
Bavarian Nordic Reports Data from a Phase 3 Clinical Trial of its VLP-Based Chikungunya Virus Vaccine in Adults ≥65 Years of Age
Bavarian Nordic A/S announced the initial safety and immunogenicity results from a randomized, double-blind, placebo-controlled Phase 3 clinical trial of a virus-like particle -based chikungunya virus vaccine candidate CHIKV VLP in healthy adults ≥65 years of age.
Emergent BioSolutions announced it has completed the sale of its travel health business to Bavarian Nordic.
Emergent BioSolutions Announces Sale of Travel Health Business to Bavarian Nordic for Up To $380 Million
Emergent BioSolutions announced that it has entered into an agreement to sell its travel health business to Bavarian Nordic for a total value of up to $380 million, including potential future milestone payments.
Bavarian Nordic A/S announced that it has entered into an agreement with Emergent BioSolutions Inc. to acquire two marketed travel vaccines, Vivotif® for the prevention of typhoid fever and Vaxchora® against cholera as well as a Phase 3 vaccine candidate for the prevention of Chikungunya virus for a total consideration of up to USD 380 million, including USD 270 million in an upfront payment and up to USD 110 million in future conditional milestone payments.
Alphalyse and Bavarian Nordic A/S significantly shorten the time necessary to document HCP impurities in COVID-19 vaccine candidate for Phase 3 clinical trial – through world’s first MS-based HCP analysis under GMP conditions
Alphalyse has performed the world’s first GMP-certified mass spectrometry (MS)-based Host Cell Protein (HCP) analysis for product release testing for Phase 3 clinical trial, after being certified by the Danish Health and Medicines Authority to perform quality control of biological API using MS-based HCP analysis under GMP.
Bavarian Nordic Enters Agreement Valued up to USD 83 Million with the U.S. Department of Defense to Further Advance the Development of Equine Encephalitis Virus Vaccine
Bavarian Nordic A/S announced a new agreement with the U.S. Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, for the advanced development of MVA-BN® WEV, a prophylactic vaccine candidate against Western, Eastern and Venezuelan equine encephalitis virus, which can cause a rare, but potentially deadly mosquito-borne illness in humans.
Bavarian Nordic Completes Enrollment in Global Phase 3 Trial of RSV Vaccine Candidate for Older Adults
Bavarian Nordic A/S (OMX: BAVA) announced today that the Company has completed the planned enrollment of subjects in the global, randomized, double-blind Phase 3 clinical trial of its investigational respiratory syncytial virus (RSV) vaccine candidate, MVA-BN ® RSV in adults ≥60 years of age.
Bavarian Nordic’s COVID-19 Booster Vaccine Candidate Demonstrates Durable Antibody Response Six Months After Vaccination in Phase 2 Clinical Trial
Bavarian Nordic A/S announced the results of a six-month follow-up analysis from a Phase 2 clinical trial of ABNCoV2, a VLP-based, non-adjuvanted COVID-19 booster vaccine candidate.
Bavarian Nordic Awarded Ten-Year Contract Amendment valued up to USD 434 million for the Supply of Smallpox and Monkeypox Vaccine to Canada
Bavarian Nordic A/S announced a revised contract with the Public Health Agency of Canada to supply doses of IMVAMUNE® smallpox vaccine at a value of approximately USD 234 million in addition to USD 180 million in contract options.
Bavarian Nordic Enters Supply Agreement with PAHO to Support Access to Monkeypox Vaccines in Latin America and the Caribbean
Bavarian Nordic A/S announced an agreement with the Pan American Health Organization to facilitate equitable access to the Company’s monkeypox vaccine for countries in Latin America and the Caribbean.
Cases of monkeypox infections reported in the latest viral outbreak have surpassed 14,000 in the U.S., according to the CDC. Some scientists believe the outbreak was predictable.
Cases of monkeypox are growing at an alarming rate and Bavarian Nordic, the company that owns one of the two approved vaccines, may no longer be able to keep up.
Bavarian Nordic Expands Capacity with U.S. Contract Manufacturer for Filling of Smallpox/Monkeypox Vaccines
U.S. FDA approved facility operated by Grand River Aseptic Manufacturing will assist in filling of already manufactured bulk vaccine to expedite deliveries of monkeypox vaccines to the U.S.
The measures will allow San Francisco and New York to coordinate efforts across different agencies and raise the public's awareness to curb the spread of monkeypox.